<rdf:RDF xmlns:rdf="http://www.openarchives.org/OAI/2.0/rdf/" xmlns:ow="http://www.ontoweb.org/ontology/1#" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:ds="http://dspace.org/ds/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/rdf/ http://www.openarchives.org/OAI/2.0/rdf.xsd">
   <ow:Publication rdf:about="oai:digibug.ugr.es:10481/61999">
      <dc:title>Topical Pioglitazone Nanoformulation for the Treatment of Atopic Dermatitis: Design, Characterization and E cacy in Hairless Mouse Model</dc:title>
      <dc:creator>Espinoza, Lupe Carolina</dc:creator>
      <dc:creator>Clares Naveros, Beatriz</dc:creator>
      <dc:subject>Atopic dermatitis</dc:subject>
      <dc:subject>Pioglitazone</dc:subject>
      <dc:subject>Nanoemulsion</dc:subject>
      <dc:subject>Pluronic F-127</dc:subject>
      <dc:description>Pioglitazone (PGZ) is a drug used to treat type 2 diabetes mellitus that has been reported to&#xd;
show additional therapeutic activities on diverse inflammatory parameters. The aim of this study&#xd;
was to optimize a topical PGZ-loaded nanoemulsion (PGZ-NE) in order to evaluate its effectiveness&#xd;
for treating atopic dermatitis (AD). The composition of the nanoformulation was established by&#xd;
pseudo-ternary diagram. Parameters such as physical properties, stability, in vitro release profile,&#xd;
and ex vivo permeation were determined. The efficacy study was carried out using oxazolone-induced&#xd;
AD model in hairless mice. PGZ-NE released the drug following a hyperbolic kinetic. Additionally,&#xd;
its properties provided high retention potential of drug inside the skin. Therapeutic benefits of&#xd;
PGZ-NE were confirmed on diverse events of the inflammatory process, such as reduction of lesions,&#xd;
enhancement of skin barrier function, diminished infiltration of inflammatory cells, and expression&#xd;
of pro-inflammatory cytokines. These results were reinforced by atomic force microscope (AFM),&#xd;
which demonstrated the ability of the formulation to revert the rigidification caused by oxazolone&#xd;
and consequently improve the elasticity of the skin. These results suggest that PGZ-NE may be a&#xd;
promising treatment for inflammatory dermatological conditions such as AD.</dc:description>
      <dc:date>2020-05-12T11:51:10Z</dc:date>
      <dc:date>2020-05-12T11:51:10Z</dc:date>
      <dc:date>2020-03-12</dc:date>
      <dc:type>journal article</dc:type>
      <dc:identifier>Espinoza, L. C., Vera-García, R., Silva-Abreu, M., Domènech, Ò., Badia, J., Rodríguez-Lagunas, M. J., ... &amp; Calpena, A. C. (2020). Topical Pioglitazone Nanoformulation for the Treatment of Atopic Dermatitis: Design, Characterization and Efficacy in Hairless Mouse Model. Pharmaceutics, 12(3), 255.</dc:identifier>
      <dc:identifier>http://hdl.handle.net/10481/61999</dc:identifier>
      <dc:identifier>10.3390/pharmaceutics12030255</dc:identifier>
      <dc:language>eng</dc:language>
      <dc:rights>http://creativecommons.org/licenses/by/3.0/es/</dc:rights>
      <dc:rights>open access</dc:rights>
      <dc:rights>Atribución 3.0 España</dc:rights>
      <dc:publisher>MDPI</dc:publisher>
   </ow:Publication>
</rdf:RDF>